Multiple myeloma highlights from ASH 2025 include two late-breaking abstracts, a phase 2 trial on a novel CAR T-cell therapy, ...

To be accepted into a clinical trial, all potential participants must meet the "eligibility criteria" by having similar ...

Discover the latest breakthroughs in multiple myeloma treatment, including CAR T-cell therapies and promising new options for ...

Oya Gilbert, a 55-year-old who was diagnosed with multiple myeloma in 2017, encourages newly diagnosed patients, especially ...

Patient-centered care in MM involves aligning treatment with evolving quality-of-life priorities, especially during remission.

Joe McDonough sat down for an interview with CURE to share his family’s story and the inspiration behind the B+ Foundation.

Estimates based on the most recent data from the NCI's Surveillance, Epidemiology, and End Results (SEER) program show that ...

C4 Therapeutics Inc. (NASDAQ:CCCC) is one of the best biotech penny stocks to buy according to analysts. On December 17, ...

The CLL17 trial showed noninferiority of fixed-duration regimens compared to continuous BTK inhibitor therapy, highlighting ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

The company has filed applications to begin clinical trials for its off-the-shelf cell therapy targeting multiple myeloma.

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...